A Review of the Virological Efficacy of the 4 World Health Organization–Recommended Tenofovir-Containing Regimens for Initial HIV Therapy
Authors:
Open Access
- 15 March 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 54 (6) , 862-875
Abstract
(See the Editorial Commentary by Kuritzkes et al, on pages 876–7 .) We systematically reviewed studies of the virological efficacy of the 4 new tenofovir (TDF)-containing regimens recommended for initial antiretroviral (ARV) therapy in the 2010 World Health Organization ARV Treatment Guidelines. Thirty-three studies assessed the efficacy of 1 or more TDF-containing regimens: TDF/lamivudine (3TC)/nevirapine (NVP) (n = 3), TDF/ emtricitabine (FTC)/NVP (n = 9), TDF/3TC/efavirenz (EFV) (n = 6), and TDF/FTC/EFV (n = 19). TDF/3TC/NVP was the least well-studied and appeared the least efficacious of the 4 regimens. In 2 comparative studies, TDF/3TC/NVP was associated with significantly more virological failure than AZT/3TC/NVP; a third study was terminated prematurely because of early virological failure. TDF/FTC/NVP was either equivalent or inferior to its comparator arms. TDF/3TC/EFV was equivalent to its comparator arms. TDF/FTC/EFV was equivalent or superior to its comparator arms. Possible explanations for these findings include the greater antiviral activity of EFV versus NVP and longer intracellular half-life of FTC-triphosphate versus 3TC-triphosphate. Further study of TDF/3TC/NVP is required before it is widely deployed for initial ARV therapy.Keywords
This publication has 36 references indexed in Scilit:
- Evaluation of the Safety and Effectiveness of Nevirapine Plus Coformulated Tenofovir/Emtricitabine as First-Line Therapy in Routine Clinical PracticeAIDS Research and Human Retroviruses, 2012
- A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patientsInternational Journal Of Clinical Practice, 2011
- Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infectionAIDS, 2011
- “Forgiving” a Missed Daily DoseAIDS Research and Human Retroviruses, 2011
- Antiretroviral Therapies in Women after Single-Dose Nevirapine ExposureNew England Journal of Medicine, 2010
- Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adultsAIDS, 2008
- Virologic, Immunologic, Clinical, Safety, and Resistance Outcomes from a Long-Term Comparison of Efavirenz-Based Versus Nevirapine-Based Antiretroviral Regimens as Initial Therapy in HIV-1—Infected PersonsHIV Research & Clinical Practice, 2008
- Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitorsVirus Research, 2008
- Once‐daily nevirapine dosing: a pharmacokinetics, efficacy and safety reviewHIV Medicine, 2007
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004